PSB-603 – 10 mg

Brand:
Cayman
CAS:
1092351-10-4
Storage:
-20
UN-No:
Non-Hazardous - /

PSB-603 is an antagonist of the adenosine A2B receptor (Ki = 0.553 nM).{42518} It is selective for adenosine A2B over A1, A2A, and A3 receptors (Kis = >10,000 nM). It reduces intracellular calcium concentrations in Jurkat T cells expressing the human A2B receptor (IC50 = 1.13 nM). PSB-603 reduces Zika viral plaque formation (IC50 = 43.8 nM) without affecting cell viability of A549 cells when used at concentrations up to 1 µM.{42519} In vivo, PSB-603 (0.25 µg/head, i.p.) delays tumor growth and reduces tumor volume and the number of pulmonary metastases in the B16 mouse model of melanoma via inhibition of induction of regulatory T cells.{42520}  

 

Available on backorder

SKU: 25637 - 10 mg Category:

Description

An adenosine A2B receptor antagonist (Ki = 0.553 nM); selective for adenosine A2B over A1, A2A, and A3 receptors (Kis = >10,000 nM); reduces intracellular calcium concentrations in Jurkat T cells expressing the human A2B receptor (IC50 = 1.13 nM); reduces Zika viral plaque formation (IC50 = 43.8 nM); delays tumor growth and reduces tumor volume and the number of pulmonary metastases in the B16 mouse model of melanoma at 0.25 µg/head, i.p.,


Formal name: 8-[4-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]phenyl]-3,9-dihydro-1-propyl-1H-purine-2,6-dione

Synonyms: 

Molecular weight: 529

CAS: 1092351-10-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Infectious Disease|Viral Diseases|Zika